Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.64 |
| ▸ | MMP1 | P03956 | 12/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.60 |
| ▸ | FCER2 | P06734 | 1/20 | 0.60 |
| ▸ | MMP3 | P08254 | 12/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 16/20 | 0.57 |
| ▸ | MMP7 | P09237 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15759462 | 1.00 | PSMB5 (0.64) | PSMB5MMP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL8468711 | 0.90 | PSMB5 (0.66) | PSMB5MMP1MMP3MMP2MMP7 | |
| SCHEMBL8510052 | 0.90 | PSMB5 (0.70) | PSMB5MMP1FCER2MMP3MMP8 | |
| SCHEMBL7066966 | 0.88 | MMP1 (0.61) | MMP1FCER2MMP3MMP8MMP2 | |
| SCHEMBL7066963 | 0.88 | MMP1 (0.61) | MMP1FCER2MMP3MMP8MMP2 | |
| SCHEMBL987191 | 0.88 | PSMB5 (0.64) | PSMB5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25139508 | 0.88 | MMP1 (0.63) | PSMB5MMP1FCER2MMP3MMP8 | |
| SCHEMBL25000564 | 0.88 | MMP1 (0.63) | PSMB5MMP1FCER2MMP3MMP8 | |
| SCHEMBL988507 | 0.87 | CHRNB2 (0.65) | PSMB5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15692406 | 0.87 | PSMB5 (0.66) | PSMB5CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180878-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | RHEA INNOVATIONS S.R.L. (IT) | 2024-06-06 | — | — | US | claimed |
| EP-4322935-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | Rhea Innovations S.R.L. (IT) | 2024-02-21 | — | — | EP | claimed |
| WO-2022219020-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | RHEA INNOVATIONS S.R.L. (IT) | 2022-10-20 | — | — | WO | claimed |
| US-10034937-B2 | Synergistic nutritional compositions and uses thereof | MEAD JOHNSON NUTRITION COMPANY (US) | 2018-07-31 | — | — | US | claimed |
| US-20170215464-A1 | NUTRITIONAL COMPOSITIONS CONTAINING DIETARY BUTYRATE AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-08-03 | — | — | US | claimed |
| US-20170157242-A1 | SYNERGISTIC NUTRITIONAL COMPOSITIONS AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-06-08 | — | — | US | claimed |
| US-20170127693-A1 | NUTRITIONAL COMPOSITIONS CONTAINING BUTYRATE AND USES THEREOF | MEAD JOHNSON NUTRITION COMPANY | 2017-05-11 | — | — | US | claimed |
| US-9255062-B2 | Fatty acid derivatives for oral administration endowed with high palatability | RHEA INNOVATIONS S.R.L. (IT) | 2016-02-09 | — | — | US | claimed |
| EP-2268605-B1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2014-06-04 | — | — | EP | claimed |
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | RHEA INNOVATIONS S.R.L. (IT) | 2011-04-28 | — | — | US | claimed |
| EP-2268605-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PAIA- TABILITY | Berni Canani, Roberto (IT) | 2011-01-05 | — | — | EP | claimed |
| WO-2009130735-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2009-10-29 | — | — | WO | claimed |
| WO-2026099710-A1 | NUTRITIONAL COMPOSITION AND THERAPEUTIC OR PREVENTIVE USE THEREOF | NUTRITECHLAB S.R.L.S. (IT) | 2026-05-15 | — | — | WO | disclosed |
| US-20240180878-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | RHEA INNOVATIONS S.R.L. (IT) | 2024-06-06 | — | — | US | disclosed |
| EP-4322935-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | Rhea Innovations S.R.L. (IT) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022219020-A1 | AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION | RHEA INNOVATIONS S.R.L. (IT) | 2022-10-20 | — | — | WO | disclosed |
| US-9255062-B2 | Fatty acid derivatives for oral administration endowed with high palatability | RHEA INNOVATIONS S.R.L. (IT) | 2016-02-09 | — | — | US | disclosed |
| EP-2268605-B1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2014-06-04 | — | — | EP | disclosed |
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | RHEA INNOVATIONS S.R.L. (IT) | 2011-04-28 | — | — | US | disclosed |
| WO-2009130735-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | FABP2, FFAR2, VIP | PSMB5 1845/4885MMP1 4498/4885CHRNB2 1195/4885 |
| US-10034937-B2 | Synergistic nutritional compositions and uses thereof | FABP2, LRBA, TSLP | PSMB5 878/4885MMP1 4634/4885CHRNB2 222/4885 |
| US-20170157242-A1 | SYNERGISTIC NUTRITIONAL COMPOSITIONS AND USES THEREOF | FABP2, LRBA, TSLP | PSMB5 878/4885MMP1 4634/4885CHRNB2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.